Evaluating the safety and efficacy of novel anti-CD7 universal CAR-T therapy in R/R T-ALL and T-LBL

Safety and efficacy of CD7-targeted CAR-T therapy in patients with R/R T-ALL and T-LBLПодробнее

Targets of CAR-T Cell TherapyПодробнее

Phase I trial of donor-derived CD7 CAR T-cells for T-ALLПодробнее

A novel subcutaneous CAR-T therapy for the treatment of hematological malignanciesПодробнее

Anti CD7 CAR T-cell therapy in T-ALLПодробнее

Novel synthetic TCR and antigen receptor (STAR) T-cell therapy for B-ALLПодробнее

Universal CAR-T therapy for T-ALLПодробнее

CAR T-Cell Therapy for Hematological Malignancies Other Than CD19Подробнее

Chimeric Antigen Receptor T-Cell Therapy, From Approval to Practice, Managing Side EffectsПодробнее

Preclinical Evaluation of CAR T Immunotherapies Using Novel Animal Models [Webinar]Подробнее

Novel strategies to optimize CAR T-cell therapyПодробнее

Sequential CD19 and BCMA CAR-TПодробнее

Breast tumor-on-chip applicable for efficacy and safety assessment of CAR-T cell therapyПодробнее

CAR T-Cell TherapyПодробнее

Chimeric Antigen Receptor T-Cell Therapy in ALLПодробнее

AbLearning™ - Episode 4: Chimeric Antigen Receptor T Cell Therapy: Efficacy & SafetyПодробнее

Mechanisms of resistance to CAR-T in ALL: T-cell fitness, antigen loss and immunological rejectionПодробнее

Safety considerations in CAR-T therapy: patient selection and side effectsПодробнее

Identifying novel antigens for TCR T-cell therapyПодробнее